Abstract 2865
Background
MSKCC and IMDC risk classification scores consist of clinical and laboratory parameters, which are able to classify patients prognosis. Baseline health related quality of life (HR-QoL) has been previously shown to have prognostic relevance in cancers. We therefore tested whether the addition of HR-QoL parameters to these tools can improve prognostic accuracy.
Methods
1100 1st line patients treated with sunitinib or pazopanib within the COMPARZ study (NCT00720941) were analyzed retrospectively. Baseline FACIT-Fatigue (F), FKSI-19 and the DRS-P subscale were used as continuous variable in prognostic factor analysis. Cox proportional hazards regression was performed to evaluate the potential prognostic ability of HR-QoL parameters on OS. Scores were adjusted for MSKCC and IMDC risk group scores separately.
Results
Univariable analysis on prognosis, adjusted for risk groups.
| HR (CI95%) | P | ||
|---|---|---|---|
| IMDC risk FACIT-F | Favorable Intermediate Unfavorable Unknown Continuous | 0.77 (0.37, 1.60) 1.42 (0.70, 2.87) 3.10 (1.50, 6.38) REFERENCE 0.97 (0.97, 0.98) | ConclusionsOur analyses indicate that baseline HR-QoL scores add to established risk prognosticators. However, only a single HR-QoL score should be used for further validation. Further study of discrimination ability is ongoing. Clinical trial identificationNCT00720941 Legal entity responsible for the studyGSK sponsored clinical study, which is the data set for the current retrospective analysis FundingMedical School Hannover, Leibniz University, McMaster University DisclosureV. Grünwald: Honoraria: BMS, Novartis, Pfizer. Consultation: BMS, Novartis, Pfizer. All other authors have declared no conflicts of interest. Resources from the same session2354 - The clinicopathologic features and treatment of 607 hindgut neuroendocrine tumor (NET) patients at a single institutionPresenter: Seung Tae Kim Session: Poster Display Resources: Abstract 2594 - Neuroendocrine carcinomas of the colorectal origin - Polish experiencePresenter: Agnieszka Kolasińska-Ćwikła Session: Poster Display Resources: Abstract 2539 - Neuroendocrine neoplasms of the appendix including goblet cell carcinoidsPresenter: Agnieszka Kolasinska-Cwikla Session: Poster Display Resources: Abstract 1245 - Prognostic validity of AJCC staging system in neuroendocrine tumors of the appendixPresenter: Amir Mehrvarz Sarshekeh Session: Poster Display Resources: Abstract 3902 - Enhancer of zest homolog 2 (EZH2) expression in well and moderately differentiated pancreatic neuroendocrine tumor (pNET)Presenter: Riccardo Marconcini Session: Poster Display Resources: Abstract 3882 - Differential clinical and pathological characteristics of hereditary neuroendocrine pancreatic tumours (NEPT)Presenter: Gema Marín Zafra Session: Poster Display Resources: Abstract 2296 - Natural course of thyroid cancer nodules compared with benign thyroid nodulesPresenter: Kyung-Jin Yun Session: Poster Display Resources: Abstract 4083 - Reassessment of proliferative activity at disease progression in neuroendocrine neoplasmsPresenter: Noemi Cicchese Session: Poster Display Resources: Abstract 3866 - 18F-FDG-PET to predict disease progression in advanced digestive neuroendocrine neoplasmsPresenter: Maria Rinzivillo Session: Poster Display Resources: Abstract 3651 - UK phase IV, observational study to assess quality of life in patients (pts) with pancreatic neuroendocrine tumours (pNETS) receiving treatment with everolimus: The “real-world” OBLIQUE studyPresenter: John Ramage Session: Poster Display Resources: Abstract This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used. For more detailed information on the cookies we use, please check our Privacy Policy.
|